Per cent case survival from cancer of the ovary, fallopian tube and peritoneum by period postdiagnosis; South Australian major public hospitals, 1984–2015 diagnoses*
| Number of cases | 1-year survival | 2-year survival | 5-year survival | 10-year survival | 20-year survival | P value† | Adjusted HR‡ (95% CIs) |
| All (n=1596) | 81.7 | 66.8 | 47.7 | 41.2 | 38.9 | – | – |
| Age at diagnosis (years): | |||||||
| <40 (n=103) | 90.3 | 84.3 | 79.2 | 72.2 | 64.4 | <0.001 | 1.00 |
| 40–49 (n=210) | 92.8 | 82.8 | 65.8 | 56.3 | 53.9 | 1.13 (0.75 to 1.71) | |
| 50–59 (n=354) | 88.8 | 69.8 | 47.0 | 39.5 | 35.8 | 1.51 (1.03 to 2.21) | |
| 60–69 (n=438) | 82.8 | 66.0 | 43.2 | 36.1 | 33.8 | 1.55 (1.07 to 2.26) | |
| 70–79 (n=324) | 71.7 | 55.2 | 34.7 | 29.6 | 29.6 | 1.87 (1.28 to 2.73) | |
| 80+ (n=167) | 64.3 | 54.2 | 43.5 | 42.0 | – | 1.63 (1.08 to 2.46) | |
| FIGO stage: | |||||||
| IA (n=212) | 99.5 | 96.1 | 89.0 | 86.1 | 80.8 | <0.001 | 1.00 |
| IB/C (n=131) | 96.1 | 91.2 | 81.3 | 76.4 | 72.1 | 1.61 (0.98 to 2.66) | |
| IIA (n=23) | 95.7 | 85.6 | 74.9 | 61.8 | 46.3 | 2.67 (1.22 to 5.81) | |
| IIB/C (n=123) | 93.9 | 86.2 | 71.9 | 58.5 | 55.3 | 2.35 (1.51 to 3.64) | |
| IIIA (n=320) | 79.9 | 60.1 | 36.6 | 29.6 | 27.4 | 5.16 (3.54 to 7.53) | |
| IIIB/C (n=376) | 82.9 | 64.8 | 35.4 | 25.5 | 23.9 | 5.43 (3.71 to 7.96) | |
| IV (n=320) | 62.8 | 42.3 | 23.2 | 20.6 | 20.1 | 7.38 (5.06 to 10.77) | |
| Unknown (n=91) | 64.5 | 47.7 | 37.3 | 34.7 | 34.7 | 5.68 (3.59 to 8.98) | |
| Differentiation: | |||||||
| Well (n=148) | 95.2 | 90.2 | 82.1 | 78.9 | 76.8 | <0.001 | 1.00 |
| Moderate (n=311) | 85.8 | 71.1 | 57.5 | 50.9 | 47.6 | 2.00 (1.35 to 2.97) | |
| Poorly/undifferentiated (n=841) | 79.4 | 63.8 | 39.7 | 31.4 | 29.9 | 2.33 (1.60 to 3.40) | |
| Unknown (n=296) | 77.4 | 58.9 | 42.5 | 39.6 | 35.6 | 2.23 (1.50 to 3.32) | |
| Histology: | |||||||
| Serous adenocarcinoma (n=789) | 86.1 | 68.3 | 41.5 | 32.6 | 29.8 | <0.001 | 1.00 |
| Mucinous adenocarcinoma (n=144) | 81.6 | 73.6 | 64.7 | 61.9 | 61.9 | 0.92 (0.68 to 1.25) | |
| Endometrioid adenocarcinoma (n=157) | 95.5 | 86.8 | 77.7 | 73.7 | 67.5 | 0.62 (0.45 to 0.86) | |
| Clear cell adenocarcinoma (n=87) | 87.2 | 71.4 | 67.7 | 59.5 | 56.1 | 1.02 (0.72 to 1.45) | |
| Adenocarcinoma (NOS) (n=417) | 67.3 | 53.4 | 38.2 | 34.3 | 33.9 | 1.20 (1.03 to 1.40) | |
| Unknown (n=2) | 50.0 | 50.0 | 50.0 | 50.0 | 50.0 | 4.98 (0.68 to 36.35) | |
| Socioeconomic (SEIFA): | |||||||
| Low (n=495) | 81.5 | 65.8 | 44.9 | 38.9 | 35.9 | 0.364 | 1.00 |
| Low/med (n=398) | 79.2 | 64.3 | 48.0 | 41.8 | 39.6 | 0.96 (0.80 to 1.15) | |
| Med/high (n=315) | 81.7 | 67.2 | 49.7 | 44.3 | 42.2 | 0.93 (0.77 to 1.13) | |
| High (n=388) | 84.6 | 70.3 | 49.2 | 41.2 | 39.5 | 0.91 (0.76 to 1.08) | |
| Geographic remoteness: | |||||||
| Low (n=1326) | 81.4 | 66.1 | 46.8 | 40.3 | 37.8 | 0.176 | 1.00 |
| Moderate (n=128) | 81.2 | 67.2 | 51.8 | 44.4 | 43.4 | 0.80 (0.62 to 1.04) | |
| High (n=142) | 85.4 | 73.3 | 52.7 | 46.6 | 45.2 | 0.84 (0.65 to 1.08) | |
| Diagnostic period (calendar years) | |||||||
| 1984–1989 (n=285) | 75.5 | 58.5 | 49.7 | 42.9 | 40.1 | 0.687 | 1.00 |
| 1990–1999 (n=596) | 80.2 | 67.0 | 47.0 | 42.3 | 40.6 | 0.87 (0.72 to 1.05) | |
| 2000–2009 (n=461) | 85.5 | 68.1 | 47.1 | 38.0 | – | 0.87 (0.71 to 1.06) | |
| 2010–2015 (n=254) | 85.7 | 74.6 | 44.1 | – | – | 0.75 (0.57 to 0.98) |
*Kaplan-Meier product-limit disease-specific estimates; date of censoring of live cases—31 December 2015.
†Derived from unadjusted Cox proportional hazards regression.
‡Derived from Cox proportional hazards regression, adjusting for other variables in the table.
FIGO, International Federation of Gynecology and Obstetrics; NOS, not otherwise specified; SEIFA, Socio-Economic Indexes for Areas.